As the accused killer of UnitedHealthcare’s CEO heads to court this week, his support has proven surprisingly enduring. https://t.co/WXio6aQVDk ...

Market Overview - The market's personality has shifted, becoming more complicated and idiosyncratic, with a focus on reasonable valuations rather than just thematic trends like AI [2][8] - Recent market action indicates a potential challenge to previous all-time highs, with broad-based participation across sectors [3][5] Sector Performance - Healthcare has emerged as a leading sector, performing well since August and being the best-performing sector this quarter, with an increase of over 10% this month [9][12] - Other strong sectors include materials and consumer discretionary, while technology has seen a decline in leadership [7][10] Investor Sentiment - Investors are currently seeking more attractive valuations and opportunities for beta, indicating a shift in focus from high-growth tech stocks to sectors with reasonable valuations [8][12] - The recent outflows from tech stocks have reached four-year extremes, suggesting a cautious approach among investors [10] Future Outlook - The market is setting up for a strong January, which is typically a favorable month for equities, while also looking ahead to 2026 [6] - Despite concerns about tech leverage, the overall sentiment remains positive, with expectations that tech will continue to lead in the coming year [19][26]

Core Insights - The US healthcare industry is experiencing new growth opportunities due to innovations such as GLP-1 agonists and gene therapies, following several years of low returns and volatility [1] Group 1: Industry Overview - The healthcare sector has faced challenges in the past three years, characterized by significant volatility and low returns [1] - Recent innovations are providing tailwinds that could enhance the sector's performance moving forward [1]

Competitive Landscape & Company Performance - Eli Lilly is outperforming Novo Nordisk due to superior execution and internal issues at Novo [2][3][5] - The market anticipates Alzheimer's data, but Lilly consistently beats expectations while Novo misses and cuts guidance [2] - Novo Nordisk's failed acquisition bid for Met Sarah indicates potential loss of momentum [3] - The analyst questions whether Novo Nordisk can recover to become an equal player in the GLP-1 duopoly [3] Valuation & Investment Strategies - The valuation gap between Eli Lilly and Novo Nordisk may be justified, but Novo Nordisk could become a value trap [4][5] - For value investing in healthcare, the analyst suggests considering Pfizer or Merck instead of Eli Lilly [4][5] - The analyst is not comfortable with Novo's trajectory and believes Lilly will continue to outperform in the coming years [5] Alternative Investment Opportunities - The analyst's top picks outside of GLP-1s include Disc Medicine (rare hematology play) and Gilead Sciences [6] - Gilead Sciences is a leader in HIV treatment and has a promising long-acting PrEP business and cell therapy [7]

Industry Overview - The healthcare landscape is evolving due to technological advances, policy shifts, and rising patient expectations, marking a pivotal moment for innovation and transformation in the industry [1] - Key trends include precision medicine, AI integration, and enhanced cybersecurity, emphasizing personalized care, operational efficiency, and system-wide resilience [1] Company Performance Tempus AI (TEM) - Tempus reported its first positive adjusted EBITDA of $1.5 million in Q3 2025, driven by strong top-line performance and disciplined operational execution [4][9] - The Genomics business saw a 33% year-over-year volume increase, with Oncology testing growing by 27% and Hereditary testing by 37% [5] - Data Licensing (Insights) business grew by 38% during the quarter, securing $150 million in new total contract value [6] - Cost discipline and efficiency efforts contributed to margin expansion, with adjusted EBITDA potentially reaching $4 million without acquisition-related expenses [7] Butterfly Network (BFLY) - Butterfly Network achieved year-over-year revenue growth while reducing cash burn, with U.S. revenues slightly increasing to $16.1 million [10] - International revenues rose by 4% year-over-year to $5.4 million, driven by higher pricing following the iQ3 launch [11] - The company reported a normalized cash burn of $3.9 million, reflecting improved operational efficiency while still investing in long-term growth areas [12] - Despite a negative adjusted EBITDA loss of $8.1 million and a gross margin of -17.5%, operational improvements were noted [13] Valuation Metrics - Tempus is trading at a forward price-to-sales (P/S) ratio of 8.18, while Butterfly Network's forward sales multiple is 6.45, indicating a discount to Tempus [14] - For 2025, the projected loss per share for Tempus is 65 cents, an improvement from the previous year's loss of $1.58 [15] - Butterfly Network's projected loss per share is 15 cents, compared to a prior-year loss of 34 cents, with stable estimates over the past 30 days [16] Investment Outlook - Tempus is viewed as the stronger investment choice due to its positive adjusted EBITDA and balanced growth across business segments [18] - Butterfly Network, while still not profitable, shows resilience and operational efficiency, making it a potential value play for investors willing to accept higher risk [19]

RT Colby Serpa (@colbyserpa)When a corporation serves a vital function that becomes relied on by a majority of citizens, the riskier its growing centralization becomes.Without competition, the centralized corporation begins to resemble a monopolistic communist government that unilaterally controls a vital good or service a majority of citizens rely on. From banks and education to healthcare and now AI.Education and healthcare are a mess and the AIs everyone relies on are controlled by a few corporations, gi ...

Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion. https://t.co/jOEXGzYsjf ...

Core Insights - The "14th Five-Year Plan" emphasizes boosting consumption by focusing on easing access and integrating service consumption, aligning with the objective laws of China's economic development [1] - Service consumption is increasingly becoming a key driver for consumption expansion and economic structure optimization, transitioning the consumption market from goods to services [1] - The growth of service consumption presents significant market opportunities for the financial sector while also raising demands for financial support to the real economy [1] Supply-Side Challenges - Service-oriented enterprises typically operate with light assets, lacking sufficient collateral to meet traditional bank credit standards, leading to difficulties in financing [2] - Traditional credit products primarily cater to large physical goods, with risk control logic and term structures not aligning with the characteristics of service consumption [2] - Existing payment systems do not fully accommodate the nature of service consumption, resulting in complex payment processes and unregulated prepayment fund management [2] Financial Support Strategies - To effectively support the expansion of service consumption, a combination of structural monetary policies and differentiated regulatory tools is necessary to encourage financial institutions to increase credit in service sectors [2] - The People's Bank of China has established a 500 billion yuan quota for service consumption and elderly care re-loan tools to guide commercial banks in enhancing credit allocation to key service areas [2] Innovation in Financial Products - Financial institutions should innovate consumer finance products and service models, developing small, flexible, and scenario-based credit products tailored to specific sectors like education and tourism [3] - There is a need to explore effective financial support models for new consumption types, including digital, green, and health consumption, to empower the development of experience, smart, and customized consumption [3] Payment Environment Optimization - It is essential to optimize the consumption payment environment to reduce transaction costs and enhance efficiency, particularly in high-frequency service scenarios [3] - Promoting the use of digital currency in sectors with high prepayment risks can help manage prepayment funds through smart contract management, mitigating risks of fund misappropriation [3] Policy and Regulatory Support - Implementing differentiated regulatory policies can encourage banks to increase credit in service consumption by providing favorable conditions regarding risk asset weight calculations and non-performing loan tolerances [4] - Establishing a unified credit information platform for service consumption can alleviate financing barriers for service enterprises and ensure convenient financing for those with good credit [4]

RT Healthcare AI Guy (@HealthcareAIGuy)NEW: Company Deep Dive — Legion HealthWe sat down with Co-Founder Arthur MacWaters to see how Legion is building an AI native, full stack telepsychiatry clinic.Inside: how full stack + AI changes care, their Tesla style path to the AI doctor, growth metrics, & more.Link 👇 https://t.co/CSywSVw5Fa ...

Abbott Laboratories has teed up the largest high-grade bridge loan this year — a $20 billion facility from Morgan Stanley — to fund its acquisition of Exact Sciences https://t.co/KeEcIJUNAD ...